High Serum miR-361-3p Predicts Early Postdischarge Infections after Autologous Stem Cell Transplantation
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background Autologous hematopoietic stem cell transplantation (AHSCT) is currently the backbone of the treatment of multiple myeloma (MM) and relapsed and refractory lymphomas. Notably, infections contribute to over 25% of fatalities among AHSCT recipients within the initial 100 days following the procedure. In this study, we aimed to evaluate three selected miRNAs: hsa-miR-155-5p, hsa-miR-320c, and hsa-miR-361-3p, in identifying AHSCT recipients at high risk of infectious events up to 100 days post-transplantation after discharge. Materials and methods The study group consisted of 58 patients (43 with MM, 15 with lymphoma) treated with AHSCT. Blood samples were collected from all patients at the same time point: on day +14 after transplantation. Results Fifteen patients (25.9%) experienced infectious complications after post-transplant discharge within the initial +100 days post-transplantation. The median time to infection onset was 44 days (interquartile range, 25–78). Four patients required hospitalization due to severe infection. High expression of hsa-miR-361-3p (fold change [FC], 1.79; P=0.0139) in the patients experiencing infectious complications and overexpression of hsa-miR-320c (FC, 2.14; P<0.0001) in patients requiring hospitalization were observed. In the multivariate model, both lymphoma diagnosis (odds ratio [OR], 6.88; 95% confidence interval [CI], 1.55–30.56; P=0.0112) and high expression of hsa-miR-361-3p (OR, 3.00; 95% CI, 1.40–6.41; P=0.0047) were independent factors associated with post-discharge infectious complications occurrence. Our model in 10-fold cross-validation preserved its diagnostic potential with an area under the receiver operating characteristic curve of 0.78 (95% CI, 0.64–0.92). Conclusion Elevated serum hsa-miR-361-3p emerges as a promising biomarker for identifying patients at risk of infection during the early post-discharge period, potentially offering optimization of the prophylactic use of antimicrobial agents tailored to the specific risk profile of each AHSCT recipient.
Abstract
Background Autologous hematopoietic stem cell transplantation (AHSCT) is currently the backbone of the treatment of multiple myeloma (MM) and relapsed and refractory lymphomas. Notably, infections contribute to over 25% of fatalities among AHSCT recipients within the initial 100 days following the procedure. In this study, we aimed to evaluate three selected miRNAs: hsa-miR-155-5p, hsa-miR-320c, and hsa-miR-361-3p, in identifying AHSCT recipients at high risk of infectious events up to 100 days post-transplantation after discharge. Materials and methods The study group consisted of 58 patients (43 with MM, 15 with lymphoma) treated with AHSCT. Blood samples were collected from all patients at the same time point: on day +14 after transplantation. Results Fifteen patients (25.9%) experienced infectious complications after post-transplant discharge within the initial +100 days post-transplantation. The median time to infection onset was 44 days (interquartile range, 25–78). Four patients required hospitalization due to severe infection. High expression of hsa-miR-361-3p (fold change [FC], 1.79; P=0.0139) in the patients experiencing infectious complications and overexpression of hsa-miR-320c (FC, 2.14; P<0.0001) in patients requiring hospitalization were observed. In the multivariate model, both lymphoma diagnosis (odds ratio [OR], 6.88; 95% confidence interval [CI], 1.55–30.56; P=0.0112) and high expression of hsa-miR-361-3p (OR, 3.00; 95% CI, 1.40–6.41; P=0.0047) were independent factors associated with post-discharge infectious complications occurrence. Our model in 10-fold cross-validation preserved its diagnostic potential with an area under the receiver operating characteristic curve of 0.78 (95% CI, 0.64–0.92). Conclusion Elevated serum hsa-miR-361-3p emerges as a promising biomarker for identifying patients at risk of infection during the early post-discharge period, potentially offering optimization of the prophylactic use of antimicrobial agents tailored to the specific risk profile of each AHSCT recipient.
참고문헌 (47)
- Passweg JR, "Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A report from the EBMT activity survey", Bone Marrow Transplant, 58, pp.647~658 (2023)
- "Summary slides & reports"[URL]
- "30 Years EBMT ACTIVITY SURVEY and 2019 annual report"[URL]
- Shah N, "Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma", Eur J Haematol, 99, pp.532~535 (2017)
- Fernandez-Avilés F, "The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies", pp.467~471 (2019), Springer
- Waszczuk-Gajda A, "Infectious complications in patients with multiple myeloma after high-dose chemotherapy followed by autologous stem cell transplant : nationwide study of the infectious complications study group of the polish adult leukemia group", Transplant Proc, 52, pp.2178~2185 (2020)
- Kim DJ, "Incidence and risk factors of opportunistic infections after autologous stem cell transplantation : a nationwide, population-based cohort study in Korea", Sci Rep, 13, pp.2551~ (2023)
- Condrat CE, "miRNAs as biomarkers in disease : latest findings regarding their role in diagnosis and prognosis", Cells, 9, pp.276~ (2020)
- Mitchell PS, "Circulating microRNAs as stable blood-based markers for cancer detection", Proc Natl Acad Sci U S A, 105, pp.10513~10518 (2008)
- Elias KM, "Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer", Elife, 6, pp.e28932~ (2017)
- Tomasik B, "Serum microRNAs as xerostomia biomarkers in patients with oropharyngeal cancer undergoing radiation therapy", Int J Radiat Oncol Biol Phys, 111, pp.1237~1249 (2021)
- Rupaimoole R, "MicroRNA therapeutics : towards a new era for the management of cancer and other diseases", Nat Rev Drug Discov, 16, pp.203~222 (2017)
- Elias K, "Identification of BRCA1", 2 mutation female carriers using circulating microRNA profiles, 2023, pp.14, 3350~
- Chouik Y, "Circulating microRNAs improve bacterial infection diagnosis and overall survival prediction in acute decompensation of liver cirrhosis", iScience, 26, pp.107427~ (2023)
- Fernández-Pato A, "Plasma miRNA profile at COVID-19 onset predicts severity status and mortality", Emerg Microbes Infect, 11, pp.676~688 (2022)
- Biswas S, "Development and validation of plasma miRNA biomarker signature panel for the detection of early HIV-1 infection", EBioMedicine, 43, pp.307~316 (2019)
- Ahmad W, "Differentially-regulated miRNAs in COVID-19 : a systematic review", Rev Med Virol, 33, pp.e2449~ (2023)
- Ljungman P, "Vaccination of hematopoietic cell transplant recipients", Bone Marrow Transplant, 44, pp.521~526 (2009)
- Ludwig H, "Recommendations for vaccination in multiple myeloma : a consensus of the European Myeloma Network", Leukemia, 35, pp.31~44 (2021)
- Ludwig H, "COVID-19 vaccination in patients with multiple myeloma : a consensus of the European Myeloma Network", Lancet Haematol, 8, pp.e934~e946 (2021)
- Hus I, "Vaccination of adult patients with hematological malignancies and patients with asplenia-guidelines of PTHiT and Infectious Diseases Working Group PALG", Acta Haematol Pol, 49, pp.93~101 (2018)
- "Common terminology criteria for adverse events (CTCAE). Version 5.0"[URL]
- Grabia S, "NormiRazor : tool applying GPU-accelerated computing for determination of internal references in microRNA transcription studies", BMC Bioinformatics, 21, pp.425~ (2020)
- Mikulski D, "High serum miR-223-3p expression level predicts complete response and prolonged overall survival in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation", Front Oncol, 13, pp.1250355~ (2023)
- Mikulski D, "Changes in the microrna expression profile in patients undergoing autologous steam cell transplantation", Blood, 138(Suppl 1), pp.4789~ (2021)
- Chang L, "miRNet 2. 0 : network-based visual analytics for miRNA functional analysis and systems biology", Nucleic Acids Res, 48, pp.W244~W251 (2020)
- Navarro A, "A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma", Oncotarget, 6, pp.1874~1883 (2015)
- Park SS, "Predictive impact of circulating microRNA-193a-5p on early relapse after autologous stem cell transplantation in patients with multiple myeloma", Br J Haematol, 189, pp.518~523 (2020)
- Rafiee M, "Circulatory miR-155 correlation with platelet and neutrophil recovery after autologous hematopoietic stem cell transplantation, a multivariate analysis", Int J Hematol, 114, pp.235~245 (2021)
- Correia CN, "Circulating microRNAs as potential biomarkers of infectious disease", Front Immunol, 8, pp.118~ (2017)
- Clare S, "Enhanced susceptibility to Citrobacter rodentium infection in microRNA-155-deficient mice", Infect Immun, 81, pp.723~732 (2013)
- Rodriguez A, "Requirement of bic", microRNA-155 for normal immune function, 2007, pp.316, 608~611
- Lind EF, "Micro-RNA 155 is required for optimal CD8+ T cell responses to acute viral and intracellular bacterial challenges", J Immunol, 190, pp.1210~1216 (2013)
- Jablonski KA, "Control of the inflammatory macrophage transcriptional signature by miR-155", PLoS One, 11, pp.e0159724~ (2016)
- Bala S, "Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection", J Transl Med, 10, pp.151~ (2012)
- Shwetha S, "Circulating miRNA profile in HCV infected serum : novel insight into pathogenesis", Sci Rep, 3, pp.1555~ (2013)
- Matamala N, "miR-320c regulates SERPINA1 expression and is induced in patients with pulmonary disease", Arch Bronconeumol, 57, pp.457~463 (2021)
- Cerón-Pisa N, "Hsa-Mir-320c, Hsa-Mir-200c-3p, and Hsa-Mir-449c-5p as potential specific miRNA biomarkers of COPD : a pilot study", Pathophysiology, 29, pp.143~156 (2022)
- Bersimbaev R, "The Plasma levels of hsa-miR-19b-3p, hsa-miR-125b-5p, and hsamiR-320c in patients with asthma, COPD and asthma-COPD overlap syndrome(ACOS)", Microrna, 10, pp.130~138 (2021)
- Deng Z, "TGF-β signaling in health, disease, and therapeutics", Signal Transduct Target Ther, 9, pp.61~ (2024)
- de Pablo R, "Sepsis-induced acute respiratory distress syndrome with fatal outcome is associated to increased serum transforming growth factor beta-1 levels", Eur J Intern Med, 23, pp.358~362 (2012)
- Wu HP, "Plasma transforming growth factor-beta1 level in patients with severe community-acquired pneumonia and association with disease severity", J Formos Med Assoc, 108, pp.20~27 (2009)
- Martin-Manso G, "Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells", Cancer Res, 68, pp.7090~7099 (2008)
- Mansfield PJ, "Thrombospondin stimulates motility of human neutrophils", J Cell Biol, 111, pp.3077~3086 (1990)
- Kościelny K, "A low thrombospondin-1 serum concentration is related to increased bacteremia risk in lymphoma patients treated with BeEAM", BEAM conditioning regimen and autologous stem cell transplantation, 2024, pp.26, e14212~
- Labiad Y, "A transcriptomic signature predicting septic outcome in patients undergoing autologous stem cell transplantation", Exp Hematol, 65, pp.49~56 (2018)
- Mitchell PS, "Circulating microRNAs as stable blood-based markers for cancer detection", Proc Natl Acad Sci U S A, 105, pp.10513~10518 (2008)